Month: June 2021

Ocugen Expands COVAXIN™ Commercialization Rights to Include Canada

Posted on by Admin


Ocugen Expands COVAXIN™ Commercialization Rights to Include Canada

 

  • Ocugen to have exclusive co-development, manufacturing, and commercialization rights to COVAXIN™ in Canada, in addition to its existing US rights

MALVERN, Pa. and HYDERABAD, India, June 03, 2021 (GLOBE NEWSWIRE) — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, and Bharat Biotech, a global leader in vaccine innovation, today announced that they have entered into an amendment to their Co-development, Supply, and Commercialization Agreement to expand Ocugen’s exclusive territory to commercialize COVAXIN™ to now also include Canada, in addition to Ocugen’s existing rights to commercialize COVAXIN™ in the United States.

“This amendment to expand our rights to commercialize COVAXIN™ into Canada speaks to our strong relationship with Bharat Biotech and our joint dedication to bring this unique yet traditional vaccine to additional countries. As we work towards the submission of the emergency use application in the US, we will simultaneously seek authorization under interim order for emergency use in Canada. We believe COVAXIN™ has the potential to play a key role in saving lives from COVID-19 in the US and Canada, as well as across the globe, due to the strong immune response it generates against multiple antigens,” said Dr. Shankar Musunuri, Chairman of the Board, Chief Executive Officer, and Co-founder of Ocugen.

“COVAXIN™ has demonstrated an excellent safety record in human clinical trials and in vaccine administration under emergency use in India. Our goal for all vaccines developed at Bharat Biotech is to provide global access. With its potential effectiveness against multiple existing and emerging variants, we believe that COVAXIN™ is an important vaccine for everyone, including children, based on its unique yet traditional vaccine platform. We are diligently working with Ocugen to bring COVAXIN™ to the US market and now to the Canadian market,” said Dr. Krishna Ella, Chairman & Managing Director of Bharat Biotech.

As consideration for Bharat Biotech’s grant of the rights to commercialize COVAXIN™ in Canada, Ocugen will make an upfront payment and milestone payment upon first commercial sale in Canada to Bharat Biotech, in addition to sharing the profit from sales of COVAXINTM in Canada. Similar to the US profit share arrangement, Ocugen will retain 45% of the profits from sales of COVAXINTM in Canada.

About COVAXIN™

COVAXIN™, India’s COVID-19 vaccine by Bharat Biotech, is developed in collaboration with the Indian Council of Medical Research (ICMR) – National Institute of Virology (NIV). COVAXIN™ is a highly purified and inactivated vaccine that is manufactured using a vero cell manufacturing platform. This platform has an excellent safety track record of more than 300 million doses of various vaccines supplied. Based on a traditional vaccine platform that has a long-established safety profile, COVAXIN™ continues to show strong results in all the studies conducted to date including a vaccine efficacy rate of 78% overall efficacy and 100% in severe COVID-19 disease, including hospitalizations, in second interim results of Bharat Biotech’s Phase 3 clinical trial.

In addition to generating strong immune response against multiple antigens, COVAXIN has been shown to generate memory T cell responses, for its multiple epitopes, indicating longevity and a rapid antibody response to future infections. With published data demonstrating a safety profile superior to published safety data from separate studies for several other vaccines, COVAXIN™ is packaged in multi-dose vials that can be stored at 2-8?C.

COVAXIN™ studies show potential effectiveness against three key variants of SARS-CoV-2. Scientists at the Indian Council of Medical Research (ICMR)-National Institute of Virology, using an in-vitro plaque reduction neutralization assay, have found that COVAXIN-vaccinated sera effectively neutralized the Brazil variant of SARS-CoV-2, B.1.128.2, the UK variant, B.1.1.7, as well as the Indian double mutant variant, B.1.617. These studies suggest that COVAXIN vaccination may be effective against multiple SARS-CoV-2 variants.

Based on the more than 30 million doses supplied in India and other countries, COVAXIN™ has an excellent safety record. COVAXIN™ is currently being administered under emergency use authorizations in 13 countries, and applications for emergency use authorization are pending in more than 60 additional countries.

About Ocugen, Inc.

Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. We are co-developing Bharat Biotech’s COVAXIN™ vaccine candidate for COVID-19 in the U.S. market. For more information, please visit http://ocugen.com/

About Bharat Biotech:

Bharat Biotech has established an excellent track record of innovation with more than 140 global patents, a wide product portfolio of more than 16 vaccines, 4 bio-therapeutics, registrations in more than 116 countries, and World Health Organization (WHO) Pre-qualifications. Located in Genome Valley in Hyderabad, India, a hub for the global biotech industry, Bharat Biotech has built a world-class vaccine & bio-therapeutics, research & product development, Bio-Safety Level 3 manufacturing, and vaccine supply and distribution.

Having delivered more than 6 billion doses of vaccines worldwide, Bharat Biotech continues to lead innovation and has developed vaccines for influenza H1N1, Rotavirus, Japanese Encephalitis, Rabies, Chikungunya, Zika and the world’s first tetanus-toxoid conjugated vaccine for Typhoid.

Bharat’s commitment to global social innovation programs and public private partnerships resulted in the introduction of path breaking WHO pre-qualified vaccines BIOPOLIO®, ROTAVAC® and Typbar TCV® combatting polio, rotavirus, typhoid infections, respectively. The recent acquisition of the rabies vaccine facility, Chiron Behring, from GlaxoSmithKline (GSK) has positioned Bharat Biotech as the largest rabies vaccine manufacturer in the world. To learn more about Bharat Biotech visit https://www.bharatbiotech.com/.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such forward-looking statements include information about qualitative assessments of available data, potential benefits, expectations for clinical trials, and anticipated timing of clinical trial readouts and regulatory submissions. This information involves risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preliminary and interim data (including the Phase 3 interim data referred to in this press release), including the possibility of unfavorable new clinical trial data and further analyses of existing clinical trial data; the risk that the results of in-vitro studies will not be duplicated in human clinical trials; the risk that clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when data from Bharat Biotech’s clinical trials will be published in scientific journal publications and, if so, when and with what modifications; whether the U.S. Food and Drug Administration (FDA) will be satisfied with the design of and results from preclinical and clinical studies of COVAXIN, which have been conducted by Bharat Biotech in India; whether and when any biologics license and/or emergency use authorization applications may be filed in the United States for COVAXIN and whether and when an application for authorization under interim order for emergency use will be filed in Canada; whether and when any such applications may be approved by the FDA or Health Canada; decisions by the FDA or Health Canada impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of COVAXIN in the United States or Canada, including development of products or therapies by other companies. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release.

Ocugen Contact:
Ocugen, Inc.
Sanjay Subramanian
CFO and Head of Corp. Dev.
IR@Ocugen.com


Media Contact:
LaVoieHealthScience
Lisa DeScenza
ldescenza@lavoiehealthscience.com
+1 9783955970

Release – Great Bear Provides Two New Detailed High-Grade Long Sections

Posted on by Admin


Great Bear Provides Two New Detailed High-Grade Long Sections and Reaches 318 Drill Holes Reported on Two Year Anniversary of LP Fault Discovery

 

June 3, 2021 – Vancouver, British Columbia, Canada – Great Bear Resources Ltd. (the “Company” or “Great Bear”, TSX-V: GBR; OTCQX: GTBAF) today reported results from its ongoing fully funded $45 million 2021 exploration program at its 100% owned flagship Dixie Project in the Red Lake district of Ontario.

This release includes two new detailed high-grade domain long sections that occur adjacent to the north of previously released domain BR7, plus drill results from 18 new LP Fault drill holes mainly targeting the peripheral bulk-tonnage domains.  318 drill holes have now been reported from the LP Fault since its discovery two years ago.

Figure 1: Upper portions of high-grade domain BR1, showing all results to date, and intersecting high-grade domain AURO20 which links BR1 to previously reported domain BR7.  The lower inset illustrates how the domains intersect in three dimensions in inclined plan view.

Table 1: All 34 drill holes that intersect the near-surface portion of high-grade domains AURO20 and BR1 along approximately 650 metres of combined strike length.  Note that assay intervals are from previously reported drill holes and have been clipped to the domains.

Drill Hole From (m) To (m) Width* (m) Gold (g/t) Domain
BR-037 86.97 102.70 15.73 4.57 AURO20
BR-067 310.00 315.00 5.00 13.00  
BR-140 227.50 232.00 4.50 12.37  
BR-141 273.00 287.00 14.00 6.28  
BR-142 184.00 193.25 9.25 2.42  
BR-143 149.50 153.50 4.00 1.81  
BR-211 43.15 50.00 6.85 8.26  
BR-212 133.25 136.25 3.00 47.81  
BR-224 294.00 305.40 11.40 1.89  
BR-037 86.97 102.70 15.73 4.57  
BR-005 180.30 183.30 3.00 7.11  
BR-035 261.00 270.50 9.50 6.02 BR1
BR-037 68.50 74.50 6.00 16.60  
BR-068 359.60 374.60 15.00 14.63  
BR-087 234.50 246.50 12.00 1.83  
BR-118 41.10 79.20 38.10 4.58  
BR-140 162.00 168.50 6.50 5.10  
BR-141 239.00 247.00 8.00 1.55  
BR-142 165.50 173.35 7.85 29.69  
BR-149 257.45 270.75 13.30 3.89  
BR-160 21.00 31.40 10.40 5.34  
BR-170 136.30 144.00 7.70 2.63  
BR-176 259.80 262.95 3.15 38.16  
BR-190 153.95 159.90 5.95 13.83  
BR-192 68.00 71.25 3.25 6.23  
BR-194 245.50 252.00 6.50 3.30  
BR-212 96.00 103.50 7.50 11.10  
BR-213 170.00 182.50 12.50 4.28  
BR-231 77.40 86.70 9.30 3.61  
BR-282 396.50 397.50 1.00 33.40  
BR-283 402.40 403.65 1.25 14.29  
DC-12-07 195.00 196.50 1.50 13.31  
DL-03-10 289.00 295.50 6.50 11.93  

* Widths are drill indicated core length, as insufficient drilling has been undertaken to determine true widths at this time.  Average grades are calculated with un-capped gold assays, as insufficient drilling has been completed to determine capping levels for higher grade gold intercepts.  Interval widths are calculated using a 0.10 g/t gold cut-off grade with up to 3 m of internal dilution of zero grade.

Figure 2: The 17 high-grade gold domains currently being modeled within the LP Fault (bulk-tonnage mineralization not shown).

Chris Taylor, President and CEO of Great Bear said, “We are very pleased to mark the two year anniversary of the LP Fault discovery by entering the final months of near-surface maiden resource estimation drilling, with results published from 318 of approximately 400 anticipated drill holes. We also provide two additional high-grade domains in this release and will continue to provide regular updates on additional domains as drilling nears completion within the various areas.”

Ongoing drilling continues to intersect high-grade and bulk-tonnage style gold mineralization at the LP Fault.  New results include:

  • 50.05 g/t gold over 2.30 metres from 315.80 to 318.10 metres downhole in drill hole BR-294.
  • 61.20 g/t gold over 1.10 metres from 143.85 to 144,95 metres downhole in drill hole BR-311.  This occurred within a broader interval assaying 3.85 g/t gold over 32.35 metres from 118.85 to 151.20 metres downhole.
  • 29.52 g/t gold over 2.50 metres from 276.55 to 279.05 metres downhole in drill hole BR-321. This occurred within a broader interval assaying 2.10 g/t gold over 49.25 metres from 254.00 to 303.25 metres downhole.

Figure 3: Map of drill progress at the LP Fault since its discovery in May 2019.  Lower image contains results from 318 drill holes.

Many of the drill holes provided in this release primarily targeted the bulk-tonnage style lower-grade envelope which occurs adjacent to, and between, the various higher-grade domains within the LP Fault.  These areas are important for future bulk tonnage gold mineral resource estimation.  Results include:

  • 1.27 g/t gold over 38.25 metres from 342.00 to 380.25 metres downhole (263 metres vertical depth) in drill hole BR-288.
  • 1.02 g/t gold over 30.00 metres from 220.00 to 250.00 metres downhole (183 metres vertical depth) in drill hole BR-321
  • 4.19 g/t gold over 14.80 metres from 43.00 to 57.80 metres downhole (38 metres vertical depth) in drill hole BR-310.
  • 1.11 g/t gold over 24.90 metres from 101.60 to 126.50 metres downhole (88 metres vertical depth) in drill hole BR-310.
  • 0.65 g/t gold over 70.20 metres from 271.50 to 341.70 metres downhole (237 metres vertical depth) in drill hole BR-279.
  • 0.63 g/t gold over 81.75 metres from 539.50 to 621.25 metres downhole (460 metres vertical depth) in drill hole BR-305.

Table 2: New drill results from the LP Fault arranged by drill section from southeast (Top) to northwest (Bottom).

Drill Hole   From (m) To (m) Width* (m) Gold (g/t)  
BR-288   342.00 380.25 38.25 1.27 19750
  including 369.00 375.90 6.90 4.19  
BR-321   220.00 250.00 30.00 1.02 20125
  including 233.00 234.00 1.00 9.53  
  and including 245.00 246.00 1.00 6.84  
  and 254.00 303.25 49.25 2.10  
  including 275.55 286.00 10.45 7.88  
  and including 276.55 279.05 2.50 29.52  
  and including 300.75 301.25 0.50 13.50  
BR-311   118.85 151.20 32.35 3.85 20550
  including 129.80 144.95 15.15 7.78  
  and including 129.80 130.30 0.50 21.50  
  and including 143.85 144.95 1.10 61.20  
  and 277.00 319.00 42.00 0.58  
BR-310   43.00 57.80 14.80 4.19 20575
  including 46.65 49.80 3.15 9.95  
  and including 52.00 53.00 1.00 10.40  
  and 101.60 126.50 24.90 1.11  
  including 111.00 113.50 2.50 3.55  
  and including 118.50 119.85 1.35 3.01  
  and including 125.20 125.70 0.50 5.20  
  and 312.20 368.00 55.80 0.44  
BR-313   23.70 26.80 3.10 6.69 20575
  and 33.35 36.10 2.75 1.76  
BR-294   311.50 329.50 18.00 6.63 21200
  including 315.80 318.10 2.30 50.05  
  and including 317.60 318.10 0.50 213.00  
BR-293   80.00 88.00 8.00 1.07 21275
  including 83.00 86.00 3.00 2.61  
  and including 85.00 86.00 1.00 5.78  
  and 243.90 246.70 2.80 1.42  
BR-292   37.50 38.70 1.20 3.97 21350
  and 250.10 278.90 28.80 0.65  
  including 262.00 265.50 3.50 3.31  
  and including 264.65 265.50 0.85 9.76  
BR-295   232.90 237.00 4.10 3.12 21350
  and 279.85 293.00 13.15 0.93  
  including 291.00 292.00 1.00 7.04  
  and 515.50 516.35 0.85 8.34  
BR-267   220.50 221.50 1.00 3.31 21775
BR-268   284.75 308.00 23.25 0.34 21775
  including 289.00 289.50 0.50 3.04  
  and including 369.60 371.50 1.90 3.12  
BR-269   394.50 419.25 24.75 0.30 21800
  and 396.00 399.00 3.00 1.10  
BR-266   309.60 316.55 6.95 1.22 21825
BR-303   447.20 473.65 26.45 0.47 21825
BR-331   121.50 124.50 3.00 2.06 21925
  and 281.40 282.40 1.00 3.30  
BR-279   78.00 79.50 1.50 3.17 22025
  and 271.50 341.70 70.20 0.65  
  including 271.50 273.00 1.50 3.50  
  and 327.00 339.00 12.00 1.68  
  including 332.85 335.00 2.15 4.95  
BR-330   145.50 198.40 52.90 0.49 22025
BR-305   539.50 621.25 81.75 0.63 22125
  including 587.80 599.40 11.60 1.01  
  and including 610.00 611.00 1.00 3.03  

* Widths are drill indicated core length, as insufficient drilling has been undertaken to determine true widths at this time.  Average grades are calculated with un-capped gold assays, as insufficient drilling has been completed to determine capping levels for higher grade gold intercepts.  Interval widths are calculated using a 0.10 g/t gold cut-off grade with up to 3 m of internal dilution of zero grade.

About High-Grade Gold Domains AURO20 and BR1

The 17 high-grade domains are structurally and geologically distinctive from the surrounding lower grade, bulk tonnage style gold mineralization.  Together, they span a strike length of 4.2 kilometres and occur within eight larger stratigraphically controlled lower grade domains.  They are characterized by high degrees of strain and/or transposed quartz vein zones following two distinct structural fabrics and  transition from upper greenschist to lower amphibolite facies metamorphism.  Gold in the high-grade domains is generally observed as free gold, is often transposed into, and overgrows the dominant structural fabrics, and is higher-grade on average than the surrounding bulk tonnage gold zones.

Domain BR1, presented in this news release, has a surface strike length of 850 metres and has been drilled to a depth of up to 430 metres (where it remains open to extension).   BR1 is a high strain zone hosted within strongly altered (albite, biotite, +/- quartz veined) felsic volcanic rocks and occurs oblique to the dominant geological contacts.  It has an average strike orientation of 290 degrees and dips 74 degrees to the north.

Domain AURO20 links BR1 to the previously released BR7 along an orientation of 280 degrees and dips 70 degrees to the north. With a strike length of 120 metres and current vertical extent of 420 metres (also open at depth), mineralization in this domain is hosted in felsic volcanic rocks and quartz veins.

Drilling is planned to intersect the various high-grade domains at 40 – 50 metre spacing.  Drilling is nearing completion in the near-surface portions of all 17 high-grade domains along more than 4 kilometres of strike length of the central LP Fault.  This drilling is expected to be completed from surface to an average of approximately 400 metres depth by year end.

Great Bear’s progress can be followed using the Company’s plan maps, long sections and cross sections, and through the VRIFY model posted at the Company’s web site at www.greatbearresources.ca.  All LP Fault drill hole highlighted assays, plus drill collar locations and orientations can also be downloaded at the Company’s web site.

Drill collar location, azimuth and dip for drill holes included in this release are provided in the table below (UTM zone 15N, NAD 83):

Hole ID Easting Northing Elevation Length Dip Azimuth
BR-266 455829 5634699 373 384 -50 38
BR-267 455882 5634676 373 414 -51 40
BR-268 455843 5634630 373 495 -50 41
BR-269 455807 5634587 374 669 -54 41
BR-279 455853 5635013 373 444 -63 225
BR-288 457924 5634143 363 678 -54 213
BR-292 456387 5634629 361 428 -58 218
BR-293 456454 5634633 362 435 -47 215
BR-294 456512 5634580 359 498 -61 218
BR-295 456491 5634769 367 633 -60 220
BR-303 456098 5635052 374 528 -50 220
BR-305 455888 5635271 375 711 -65 226
BR-310 456956 5634112 356 423 -56 211
BR-311 456976 5634068 356 363 -56 212
BR-313 456923 5634044 356 150 -56 211
BR-321 457469 5634134 358 493 -55 203
BR-330 455800 5634958 373 336 -60 227
BR-331 455912 5635006 372 428 -60 222

About the Dixie Project

The Dixie Project is 100% owned, comprised of 9,140 hectares of contiguous claims that extend over 22 kilometres, and is located approximately 25 kilometres southeast of the town of Red Lake, Ontario. The project is accessible year-round via a 15 minute drive on a paved highway which runs the length of the northern claim boundary and a network of well-maintained logging roads.

The Dixie Project hosts two principal styles of gold mineralization:

  • High-grade gold in quartz veins and silica-sulphide replacement zones (Dixie Limb, Hinge and Arrow zones). Hosted by mafic volcanic rocks and localized near regional-scale D2 fold axes.  These mineralization styles are also typical of the significant mined deposits of the Red Lake district.
  • High-grade disseminated gold with broad moderate to lower grade envelopes (LP Fault).  The LP Fault is a significant gold-hosting structure which has been seismically imaged to extend to 14 kilometres depth (Zeng and Calvert, 2006), and has been interpreted by Great Bear to have up to 18 kilometres of strike length on the Dixie property.  High-grade gold mineralization is controlled by structural and geological contacts, and moderate to lower-grade disseminated gold surrounds and flanks the high-grade intervals.  The dominant gold-hosting stratigraphy consists of felsic sediments and volcanic units.

About Great Bear

Great Bear Resources Ltd. is a well-financed gold exploration company managed by a team with a track record of success in mineral exploration.  Great Bear is focused in the prolific Red Lake gold district in northwest Ontario, where the company controls over 200 km2 of highly prospective tenure across 4 projects, all 100% owned: The flagship Dixie Project, the Pakwash Property, the Sobel Property, and the Red Lake North Property, all of which are accessible year-round through existing roads.

QA/QC and Core Sampling Protocols

Drill core is logged and sampled in a secure core storage facility located in Red Lake Ontario.  Core samples from the program are cut in half, using a diamond cutting saw, and are sent to Activation Laboratories in Ontario, an accredited mineral analysis laboratory, for analysis. All samples are analysed for gold using standard Fire Assay-AA techniques. Samples returning over 10.0 g/t gold are analysed utilizing standard Fire Assay-Gravimetric methods.  Pulps from approximately 5% of the gold mineralized samples are submitted for check analysis to a second lab.  Selected samples are also chosen for duplicate assay from the coarse reject of the original sample.  Selected samples with visible gold are also analyzed with a standard 1 kg metallic screen fire assay.  Certified gold reference standards, blanks and field duplicates are routinely inserted into the sample stream, as part of Great Bear’s quality control/quality assurance program (QAQC).  No QAQC issues were noted with the results reported herein. 

Qualified Person and NI 43-101 Disclosure

Mr. R. Bob Singh, P.Geo, VP Exploration, and Ms. Andrea Diakow P.Geo, Exploration Manager for Great Bear are the Qualified Persons as defined by National Instrument 43-101 responsible for the accuracy of technical information contained in this news release.

ON BEHALF OF THE BOARD

“Chris Taylor”

Chris Taylor, President and CEO

Investor Inquiries:
Mr. Knox Henderson
Tel: 604-646-8354
Direct: 604-551-2360
info@greatbearresources.ca
www.greatbearresources.ca

Cautionary note regarding forward-looking statements

This release contains certain “forward looking statements” and certain “forward-looking information” as defined under applicable Canadian and U.S. securities laws. Forward-looking statements and information can generally be identified by the use of forward-looking terminology such as “may”, “will”, “should”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “continue”, “plans” or similar terminology. The forward-looking information contained herein is provided for the purpose of assisting readers in understanding management’s current expectations and plans relating to the future. Readers are cautioned that such information may not be appropriate for other purposes.

Forward-looking information are based on management of the parties’ reasonable assumptions, estimates, expectations, analyses and opinions, which are based on such management’s experience and perception of trends, current conditions and expected developments, and other factors that management believes are relevant and reasonable in the circumstances, but which may prove to be incorrect.

Such factors, among other things, include: impacts arising from the global disruption caused by the Covid-19 coronavirus outbreak, business integration risks; fluctuations in general macroeconomic conditions; fluctuations in securities markets; fluctuations in spot and forward prices of gold or certain other commodities; change in national and local government, legislation, taxation, controls, regulations and political or economic developments; risks and hazards associated with the business of mineral exploration, development and mining (including environmental hazards, industrial accidents, unusual or unexpected formations pressures, cave-ins and flooding); discrepancies between actual and estimated metallurgical recoveries; inability to obtain adequate insurance to cover risks and hazards; the presence of laws and regulations that may impose restrictions on mining; employee relations; relationships with and claims by local communities and indigenous populations; availability of increasing costs associated with mining inputs and labour; the speculative nature of mineral exploration and development (including the risks of obtaining necessary licenses, permits and approvals from government authorities); and title to properties.

Great Bear undertakes no obligation to update forward-looking information except as required by applicable law. Such forward-looking information represents management’s best judgment based on information currently available. No forward-looking statement can be guaranteed and actual future results may vary materially. Accordingly, readers are advised not to place undue reliance on forward-looking statements or information.

Release – Kratos Appoints Deanna Lund to Board of Directors

Posted on by Admin


Kratos Appoints Deanna Lund to Board of Directors

 

SAN DIEGO, 
June 03, 2021 (GLOBE NEWSWIRE) — 
Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a leading National Security Solutions provider, is pleased to announce the appointment of  Deanna Hom Lund to the Company’s Board of Directors.

Ms. Lund has served as Kratos’ Executive Vice President and Chief Financial Officer since 
April 2009.  Ms. Lund was Kratos’ Senior Vice President and Chief Financial Officer from 
April 2004 to 
March 2009. Prior to joining Kratos,  Ms. Lund was the Vice President and Corporate Controller of 
Titan Corporation from 
July 1998 to 2004.  Ms. Lund was also Titan’s Corporate Controller from 
December 1996 to 
July 1998, and its Corporate Manager of Operations Analysis from 1993 to 1996. Prior to Titan,  Ms. Lund worked for 
Arthur Andersen, LLP.  Ms. Lund received her bachelor’s degree in Accounting from 
San Diego State University, magna cum laude, and is a Certified Public Accountant.

William Hoglund, the Chairman of the Board, said, “We are delighted that Deanna will be joining our Board. She is a strategic, engaging leader that brings a wealth of skills and experience in finance and corporate development. She will be an excellent addition to the Board as Kratos continues to execute its vision and strategy to be the go-to provider of affordable products, systems and solutions that are rapidly developed, demonstrated and fielded for the War Fighter.”

Upon the unanimous recommendation of the Board’s 
Nomination & Governance Committee, the Board of Directors also voted to increase the size of the Company’s Board to nine members, with  Ms. Lund filling one of the two vacancies. The Board of Directors expects to fill the second vacancy within the next 18 months when a suitable candidate is identified.

About Kratos Defense & Security Solutions

Kratos Defense & Security Solutions, Inc. (NASDAQ:KTOS) develops and fields transformative, affordable technology, platforms and systems for United States National Security related customers, allies and commercial enterprises. Kratos is changing the way breakthrough technology for these industries are rapidly brought to market through proven commercial and venture capital backed approaches, including proactive research and streamlined development processes. At Kratos, affordability is a technology and we specialize in unmanned systems, satellite communications, cyber security/warfare, microwave electronics, missile defense, hypersonic systems, training, combat systems and next generation turbo jet and turbo fan engine development. For more information go to www.KratosDefense.com.

Notice Regarding Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended 
December 27, 2020, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the 
SEC by Kratos.

Press Contact:
Yolanda White
858-812-7302 Direct

Investor Information:
877-934-4687
investor@kratosdefense.com


Source: Kratos Defense & Security Solutions, Inc.

Release – Indonesia Energy Corporation Participates in Noble Capital Markets Video Interview

Posted on by Admin


Indonesia Energy Corporation Participates in Noble Capital Markets Video Interview

 

President Frank Ingriselli Provides Updates on IEC’s New Drilling Program at Kruh Block and Anticipated Milestones for IEC

JAKARTA, INDONESIA AND DANVILLE, CA / ACCESSWIRE / June 3, 2021 / Indonesia Energy Corporation (NYSE American:INDO) (“IEC”), an oil and gas exploration and production company focused on Indonesia, today announced their participation in a pre-recorded Noble Capital Markets’ C-Suite Interview Series, presented by Channelchek.

Indonesia Energy President Frank Ingriselli sat down with Noble Capital Markets Senior Research Analyst Michael Heim for this exclusive interview.

The interview was recorded on May 26, 2021, and is available now on Channelchek. at the following link: https://www.channelchek.com/channelcast-detail/230

Topics covered include an update on the current drilling progress at IEC’s Kruh Block and anticipated upcoming milestones for Kruh Block, as well as expectations for exploration and drilling at IEC’s gas-prone Citarum Block.

About Indonesia Energy Corporation Limited

Indonesia Energy Corporation Limited (NYSE American: INDO) is a publicly traded energy company engaged in the acquisition and development of strategic, high growth energy projects in Indonesia. IEC’s principal assets are its Kruh Block (63,000 acres) located onshore on the Island of Sumatra in Indonesia and its Citarum Block (1,000,000 acres) located onshore on the Island of Java in Indonesia. IEC is headquartered in Jakarta, Indonesia and has a representative office in Danville, California. For more information on IEC, please visit www.indo-energy.com.

Cautionary Statement Regarding Forward-Looking Statements

All statements in this press release and in the interview referenced herein of Indonesia Energy Corporation Limited (“IEC”) and its representatives and partners that are not based on historical fact are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Acts”). In particular, when used in the preceding discussion, the words “estimates,” “believes,” “hopes,” “expects,” “intends,” “on-track”, “plans,” “anticipates,” or “may,” and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Acts and are subject to the safe harbor created by the Acts. Any statements made in this news release other than those of historical fact, about an action, event or development, are forward-looking statements. While management has based any forward-looking statements contained herein on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of the IEC’s control, that could cause actual results (including the results of IEC’s drilling and exploration activities as discussed in the interview referenced herein) to materially and adversely differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth in the Risk Factors section of the Company’s annual report on Form 20-F for the fiscal year ended December 31, 2020 filed on May 17, 2021 with the Securities and Exchange Commission (SEC). Copies are of such documents are available on the SEC’s website, www.sec.gov. IEC undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Company Contact:

Frank C. Ingriselli
President, Indonesia Energy Corporation Limited
Frank.Ingriselli@Indo-Energy.com

SOURCE: Indonesia Energy Corporation Limited

Kratos Appoints Deanna Lund to Board of Directors

Posted on by Admin


Kratos Appoints Deanna Lund to Board of Directors

 

SAN DIEGO, 
June 03, 2021 (GLOBE NEWSWIRE) — 
Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a leading National Security Solutions provider, is pleased to announce the appointment of  Deanna Hom Lund to the Company’s Board of Directors.

Ms. Lund has served as Kratos’ Executive Vice President and Chief Financial Officer since 
April 2009.  Ms. Lund was Kratos’ Senior Vice President and Chief Financial Officer from 
April 2004 to 
March 2009. Prior to joining Kratos,  Ms. Lund was the Vice President and Corporate Controller of 
Titan Corporation from 
July 1998 to 2004.  Ms. Lund was also Titan’s Corporate Controller from 
December 1996 to 
July 1998, and its Corporate Manager of Operations Analysis from 1993 to 1996. Prior to Titan,  Ms. Lund worked for 
Arthur Andersen, LLP.  Ms. Lund received her bachelor’s degree in Accounting from 
San Diego State University, magna cum laude, and is a Certified Public Accountant.

William Hoglund, the Chairman of the Board, said, “We are delighted that Deanna will be joining our Board. She is a strategic, engaging leader that brings a wealth of skills and experience in finance and corporate development. She will be an excellent addition to the Board as Kratos continues to execute its vision and strategy to be the go-to provider of affordable products, systems and solutions that are rapidly developed, demonstrated and fielded for the War Fighter.”

Upon the unanimous recommendation of the Board’s 
Nomination & Governance Committee, the Board of Directors also voted to increase the size of the Company’s Board to nine members, with  Ms. Lund filling one of the two vacancies. The Board of Directors expects to fill the second vacancy within the next 18 months when a suitable candidate is identified.

About Kratos Defense & Security Solutions

Kratos Defense & Security Solutions, Inc. (NASDAQ:KTOS) develops and fields transformative, affordable technology, platforms and systems for United States National Security related customers, allies and commercial enterprises. Kratos is changing the way breakthrough technology for these industries are rapidly brought to market through proven commercial and venture capital backed approaches, including proactive research and streamlined development processes. At Kratos, affordability is a technology and we specialize in unmanned systems, satellite communications, cyber security/warfare, microwave electronics, missile defense, hypersonic systems, training, combat systems and next generation turbo jet and turbo fan engine development. For more information go to www.KratosDefense.com.

Notice Regarding Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended 
December 27, 2020, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the 
SEC by Kratos.

Press Contact:
Yolanda White
858-812-7302 Direct

Investor Information:
877-934-4687
investor@kratosdefense.com


Source: Kratos Defense & Security Solutions, Inc.

Pyxis Tankers Inc. (PXS) – Slightly Better Quarter and Acquisition Set to Close in 3Q2021

Posted on by Admin

Thursday, June 03, 2021

Pyxis Tankers Inc. (PXS)
Slightly Better Quarter and Acquisition Set to Close in 3Q2021

Pyxis Tankers Inc is a United States-based international maritime transportation company which focuses on the product tanker sector. It owns a fleet which comprises of double hull product tankers employed under a mix of short- and medium-term time charters and spot charters. The fleet owned by the company includes Pyxis Epsilon, Pyxis Theta, Pyxis Malou, Pyxis Delta, Northsea Alpha, and Northsea Beta. Each of the vessels in the fleet is capable of transporting refined petroleum products, such as naphtha, gasoline, jet fuel, kerosene, diesel, fuel oil, and other liquid bulk items, such as vegetable oils and organic chemicals.

Poe Fratt, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Adjusted EBITDA of $0.8 million was better than expected. Higher TCE revenue of $4.3 million and higher rates of $12.7k/day drove the positive variance.

    Increasing 2021 EBITDA estimate to $6.5 million from $5.5 million to reflect the positive quarterly variance and timing of the pending acquisition.  TCE revenue of $21.7 million is positively impacted by higher TCE rates of $12.3k/day and more ownership days of 1,976 …



This research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Release – Avivagen Inc. Announces Results for the Second Quarter Ending April 30 2021

Posted on by Admin


Avivagen Inc. Announces Results for the Second Quarter Ending April 30, 2021

 

• Record 64.5 tonne order for OxC-betaTM Livestock over 18 months
• New expansion efforts and customer wins in Central and South America
• Launch of first product for human health.

Ottawa, ON /Business Wire/ June 2, 2021/ Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, has announced its unaudited financial results for the second quarter of 2021.

Milestones achieved in Q2 2021 include:
• Secured its largest recurring order to date for OxC-betaTM Livestock, an 18-month contract at four tonnes per month for use in Mexico. The 64.5 tonne total order is the largest to date in both size and length of contract, and a direct result of the Meyenberg International Group agreement finalized in Q2.
• Selected Meyenberg International Group to spearhead expansion efforts in Central and South America.
• In conjunction with Mimi’s Rock Corp., announced the launch of Dr. Tobias Beta Blend on Amazon.com – Avivagen’s first product designed for human consumption.
• Announced the closing of its oversubscribed $7.5 million bought deal unit offering.
• Announced the publication of its New Zealand OxC-betaTM Livestock dairy trial for use against sub-clinical mastitis in the New Zealand Veterinary Journal, and its upcoming publication of research highlighting the benefits of OxC-betaTM Livestock for Broiler Poultry in Poultry Science.

Since the end of the quarter Avivagen also announced it had:
• Secured a new customer win in Western Mexico.
• Terminated its previous exclusive U.S. sales and distribution agreement and initiated discussions with potential partners to ramp up sales efforts in the lucrative region.
• Recorded its first order from Brazil, received on May 28, 2021.
• Secured first order with major swine and poultry producer in Thailand following numerous trials.

Second Quarter April 30, 2021, Financial Results
The Company’s unaudited Financial Statements for the second quarter ended April 30, 2021 and the accompanying Management’s Discussion and Analysis have been filed on the System for Electronic Document Analysis and Retrieval and are available via its website (www.sedar.com). The financial information for the second quarter ended April 30, 2021, should be read in conjunction with the Company’s unaudited Financial Statements as well as its Management’s Discussion and Analysis for the second quarter ended April 30, 2021.

The Company reported revenues of $159,614 ($29,625 in the quarter ending April 30, 2020) and a comprehensive loss of $(2,197,649) for the quarter ending April 30, 2021. This compares to a comprehensive loss in the quarter ending April 30, 2020 of $(1,393,497).

As reported in the statements of cash flows, the April 30, 2021 quarter comprehensive loss of $(2,197,649) consists of $1,181,373 in non-cashflow items such as share-based payment expense, depreciation, and adjustments to the Company’s ACOA loans. The Company reported $724,505 in interest accretion and adjustments related to the ACOA loans as a result of an increase in management’s estimate of future revenues. As noted, this ACOA adjustment is a non-cash adjustment in the quarter ending April 30, 2021.

The ACOA loans are interest-free and repayments are calculated as 10% of the future revenues and are payable on June 30th of each year. The carrying value has been discounted using a rate of 35% based on the expected timing and amounts of future repayments of the loans. Consequently, the carrying value of the ACOA loans requires regular assessment and adjustment based on management’s estimate of future revenues, with any adjustment being recorded as finance cost on the statement of comprehensive income with an equal increase in the ACOA debt liability on the statement of financial position. In light of the recent press releases announcing future and recurring order for customers in Mexico, Philippines, and Thailand, management increased its estimate of future revenues and therefore adjusted the carrying value of the ACOA loans accordingly.

The Company’s working capital increased by $949,353 as management invested in additional volumes of inventory to support future sales and increased prepaids expenses and trade receivables.

As at April 30, 2021, the Company reported total assets of $5,985,104 (current assets of $5,675,117), total liabilities of $7,163,307, and shareholders’ deficit of ($1,178,203).

Significant financing inflows during the quarter ending April 30, 2021, was an offering of 15,000,000 units of the Company at $0.50 per unit for aggregate gross proceeds of $7,500,000. The offering closed on February 16th, 2021.

Each unit consisted of one common share in the capital of the Company (each a “Common Share”) and one half of one Common Share purchase warrant (each whole warrant, a “Warrant”). Each Warrant will be exercisable to acquire one Common Share until February 16, 2024 at an exercise price of $0.75 per share. The net proceeds of the Offering have been and will be used to fund research and development expenses, sales and marketing costs, product registration, interest expense, working capital and general corporate purposes.

About Avivagen
Avivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance. It is a public corporation traded on the TSX Venture Exchange under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada. For more information, visit www.avivagen.com. The contents of the website are expressly not incorporated by reference in this press release.

About OxC-beta™ Technology and OxC-beta™ Livestock
Avivagen’s OxC-beta™ technology is derived from Avivagen discoveries about ?-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colours. Through support of immune function the technology provides a non-antibiotic means of promoting health and growth. OxC-beta™ Livestock is a proprietary product shown to be an effective and economic alternative to the antibiotics commonly added to livestock feeds. The product is currently available for sale in the United States, Philippines, Mexico, Taiwan, New Zealand, Thailand, Brazil, Australia, and Malaysia.

Avivagen’s OxC-beta™ Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta™ Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics.

Forward Looking Statements
This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “aim”, “anticipate”, “appear”, “believe”, “consider”, “could”, “estimate”, “expect”, “if”, “intend”, “goal”, “hope”, “likely”, “may”, “plan”, “possibly”, “potentially”, “pursue”, “seem”, “should”, “whether”, “will”, “would” and similar expressions. Statements set out in this news release relating to Avivagen’s expectations as to future growth and results, the anticipated continuation of shipments to customers based on recurring orders, future plans for sales in the United States, the planned use of proceeds of the financing discussed above, Avivagen’s expectations as to growth in demand for Avivagen’s products, the possibility for OxC-beta™ Livestock to replace antibiotics in livestock feeds as well as fill a critical need for health support in certain livestock applications where antibiotics are precluded and the size of market opportunities are all forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. For instance, initial orders may not result in new orders for Avivagen’s products, despite receipt of the purchase order timing, delivery or fulfilment of orders of product could be delayed for a number of reasons, some of which are outside of Avivagen’ s control, which could result in anticipated revenues from such sales being delayed or in the most serious cases eliminated, actions taken by Avivagen’ s customers and factors affecting the business and financial viability of Avivagen’ s customers can have a negative impact on the expectation of future sales and revenues, customer plans may change due to many reasons, demand for Avivagen’s products may not continue to grow and could decline, Avivagen’s products may not gain market acceptance or regulatory approval in new jurisdictions or for new applications and may not be widely accepted as a replacement for antibiotics in livestock feeds, in each case due to many factors, many of which are outside of Avivagen’s control. Readers are referred to the risk factors associated with the business of Avivagen set out in Avivagen’s most recent management’s discussion and analysis of financial condition available at www.SEDAR.com. Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information:
Avivagen Inc.
Drew Basek
Director of Investor Relations
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6 Phone: 416-540-0733
E-mail: d.basek@avivagen.com

Kym Anthony
Chief Executive Officer
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6 Head Office Phone: 613-949-8164
Website: www.avivagen.com
Copyright © 2021 Avivagen Inc. OxC-beta™ is a trademark of Avivagen Inc.

Eagle Bulk Shipping (EGLE) – Fleet Renewal Program Remains Active

Posted on by Admin

Thursday, June 03, 2021

Eagle Bulk Shipping (EGLE)
Fleet Renewal Program Remains Active

Eagle Bulk Shipping Inc. is a US-based drybulk owner-operator focused on the Supramax/Ultramax mid-size asset class, which ranges from 50,000 and 65,000 deadweight tons in size; these vessels are equipped with onboard cranes allowing for the self-loading and unloading of cargoes, a feature which distinguishes them from the larger classes of drybulk vessels and provides for greatly enhanced flexibility and versatility- both with respect to cargo diversity and port accessibility. The Company transports a broad range of major and minor bulk cargoes around the world, including coal, grain, ore, pet coke, cement, and fertilizer. Eagle operates out of three offices, Stamford (headquarters), Singapore, and Hamburg, and performs all aspects of vessel management in-house including: commercial, operational, technical, and strategic.

Poe Fratt, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Two Ultra acquisitions look attractive. Two 2015-built Ultras, built at Jiang Hontang, will be acquired for a total of $44 million in late 3Q2021, Both Ultras, which are equipped with scrubbers, completed surveys over the past year.

    Pro forma fleet expands to 53 and is balanced with fleet consists of 26 Ultras and 27 Supras.  Sale of older Supra also helps fleet profile. The sale of the Tern, a 2003-built Supra, for $9.7 million was also announced. This move is positive and it leaves only two other 2003-built Supras left to sell …



This research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Release – Gray Amends Merger Agreement With Meredith Corporation

Posted on by Admin


Gray Amends Merger Agreement With Meredith Corporation

 

ATLANTA, June 03, 2021 (GLOBE NEWSWIRE) — Gray Television, Inc. (“Gray”) (NYSE: GTN) today confirmed that Meredith Corporation (“Meredith”) recently informed Gray that, after announcing the definitive agreement with Gray, it had received an unsolicited proposal to acquire its Local Media Group (“LMG”) division, including all of Meredith’s broadcast television stations, from another party. Gray subsequently offered to amend the parties’ Merger Agreement to increase the total consideration payable by Gray from approximately $14.50 per share in cash, or $2.7 billion in total enterprise value (after the spin off of Meredith’s National Media Group to the current Meredith shareholders), to $16.99 per share in cash, or $2.825 billion in total enterprise value; to increase certain fees due to the other party under certain termination events under the Merger Agreement; and to make certain other revisions. On June 2, 2021, Gray and Meredith entered into an amendment to reflect the revised terms.

Meredith has informed Gray that its Board of Directors unanimously approved the revised Gray proposal, citing superior certainty of value, regulatory considerations, path to close and expected timing.

Gray remains committed to moving forward with its pending acquisition of Meredith’s local television stations. Gray continues to believe that the proposed Gray/Meredith transaction is in the best interests of the shareholders of both Gray and Meredith, as well as the companies’ respective employees, business partners, and local communities.

Meredith’s Board continues to recommend that its shareholders approve the proposed transaction with Gray. In addition, Meredith shareholders with voting control of approximately 87% of the issued and outstanding Class B common stock of Meredith have entered into a voting and support agreement that generally requires that those shareholders vote their shares in favor of the adoption of the Merger Agreement and take certain other actions to support the transactions contemplated by the Merger Agreement (including voting against any competing proposal) as long as the Merger Agreement has not been terminated.

Gray continues to expect that the Meredith transaction, even as amended, will be significantly accretive to free cash flow per share. To date, Gray has identified an estimated $55 million in synergies annualized for the first full calendar year following the closing. Including these anticipated $55 million of synergies, the revised purchase price for Gray’s acquisition of Meredith represents a multiple of approximately 8.3 times a blended average of the Meredith television stations’ 2019/2020 operating cash flow.

The transaction is subject to approval by Meredith’s shareholders and customary closing conditions and regulatory approvals, including certain consents necessary to effectuate the spin-off of Meredith’s National Media Group immediately prior to the closing of Gray’s acquisition of Meredith. Expected strong free cash flow generation through the closing of all pending transactions and throughout 2021 and 2022 is anticipated to allow Gray to deleverage its capital structure following the closing. Assuming a year-end 2021 closing, Gray anticipates that its total leverage ratio, net of all cash, would approximate 5.4 times on a trailing eight-quarter operating cash flow, including estimated annualized synergies from all announced transactions.

About Gray:

Gray Television is a television broadcast company headquartered in Atlanta, Georgia. Gray is the largest owner of top-rated local television stations and digital assets in the United States. Gray currently owns and/or operates television stations and leading digital properties in 94 television markets that collectively reach approximately 24% of U.S. television households. During 2020, Gray’s stations were ranked first in 70 markets, and ranked first and/or second in 86 markets, as calculated by Comscore’s audience measurement service. Gray also owns video program production, marketing, and digital businesses including Raycom Sports, Tupelo Honey, and RTM Studios, the producer of PowerNation programs and content, and it is the majority owner of Swirl Films.

Gray Contacts:  

Website: www.gray.tv

Hilton H. Howell, Jr., Chairman, President and Chief Executive Officer, 404-266-5512
Jim Ryan, Executive Vice President and Chief Financial Officer, 404-504-9828
Kevin P. Latek, Executive Vice President, Chief Legal and Development Officer, 404-504-9828

Forward-Looking Statements:

This press release contains certain forward looking statements that are based largely on Gray’s current expectations and reflect various estimates and assumptions by Gray. These statements are statements other than those of historical fact, and may be identified by words such as “estimates”, “expect,” “anticipate,” “will,” “implied,” “assume” and similar expressions. Forward looking statements are subject to certain risks, trends and uncertainties that could cause actual results and achievements to differ materially from those expressed in such forward looking statements. Such risks, trends and uncertainties, which in some instances are beyond Gray’s control, include Gray’s ability to complete its pending acquisition of Meredith or other pending transactions, on the terms and within the timeframe currently contemplated, any material regulatory or other unexpected requirements in connection therewith, or whether expected synergies can be achieved on a timely basis or at all, the impact of recently completed transactions, estimates of future retransmission revenue, future expenses and other future events. Gray is subject to additional risks and uncertainties described in Gray’s quarterly and annual reports filed with the Securities and Exchange Commission from time to time, including in the “Risk Factors,” and management’s discussion and analysis of financial condition and results of operations sections contained therein, which reports are made publicly available via its website, www.gray.tv. Any forward-looking statements in this communication should be evaluated in light of these important risk factors. This presentation reflects management’s views as of the date hereof. Except to the extent required by applicable law, Gray undertakes no obligation to update or revise any information contained in this communication beyond the date hereof, whether as a result of new information, future events or otherwise.

No Offer or Solicitation

This communication is for informational purposes only and is neither an offer to purchase, nor a solicitation of an offer to sell, any securities or the solicitation of any vote in any jurisdiction pursuant to the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law.

Additional Information and Where To Find It

This communication is not a solicitation of a proxy from any shareholder of Meredith. Gray expects Meredith will file relevant materials with the Securities and Exchange Commission in connection with the proposed transactions, including a proxy. INVESTORS OF MEREDITH ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT AND OTHER RELEVANT MATERIALS CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT MEREDITH, GRAY AND THE PROPOSED MERGER. Investors may obtain a free copy of these materials (when they are available) and other documents filed by Meredith with the SEC at the SEC’s website at www.sec.gov.

Participants in the Merger Solicitation

Gray, Meredith and their respective executive officers and directors may be deemed to be participants in the solicitation of proxies from the security holders of Meredith in connection with the proposed merger and related spin-off. Information about Gray’s directors and executive officers is available in its definitive proxy statement, dated March 25, 2021, for its 2021 annual meeting of shareholders. Information about Meredith’s directors and executive officers is available in Meredith’s definitive proxy statement, dated September 25, 2020, for its 2020 annual meeting of shareholders. Other information regarding the participants and description of their direct and indirect interests, by security holdings or otherwise, will be contained in the proxy statement and Form 10 registration statement regarding the proposed merger and related spin-off that Meredith will file with the SEC when it becomes available.

Release – Ocugen Expands COVAXIN Commercialization Rights to Include Canada

Posted on by Admin


Ocugen Expands COVAXIN™ Commercialization Rights to Include Canada

 

  • Ocugen to have exclusive co-development, manufacturing, and commercialization rights to COVAXIN™ in Canada, in addition to its existing US rights

MALVERN, Pa. and HYDERABAD, India, June 03, 2021 (GLOBE NEWSWIRE) — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, and Bharat Biotech, a global leader in vaccine innovation, today announced that they have entered into an amendment to their Co-development, Supply, and Commercialization Agreement to expand Ocugen’s exclusive territory to commercialize COVAXIN™ to now also include Canada, in addition to Ocugen’s existing rights to commercialize COVAXIN™ in the United States.

“This amendment to expand our rights to commercialize COVAXIN™ into Canada speaks to our strong relationship with Bharat Biotech and our joint dedication to bring this unique yet traditional vaccine to additional countries. As we work towards the submission of the emergency use application in the US, we will simultaneously seek authorization under interim order for emergency use in Canada. We believe COVAXIN™ has the potential to play a key role in saving lives from COVID-19 in the US and Canada, as well as across the globe, due to the strong immune response it generates against multiple antigens,” said Dr. Shankar Musunuri, Chairman of the Board, Chief Executive Officer, and Co-founder of Ocugen.

“COVAXIN™ has demonstrated an excellent safety record in human clinical trials and in vaccine administration under emergency use in India. Our goal for all vaccines developed at Bharat Biotech is to provide global access. With its potential effectiveness against multiple existing and emerging variants, we believe that COVAXIN™ is an important vaccine for everyone, including children, based on its unique yet traditional vaccine platform. We are diligently working with Ocugen to bring COVAXIN™ to the US market and now to the Canadian market,” said Dr. Krishna Ella, Chairman & Managing Director of Bharat Biotech.

As consideration for Bharat Biotech’s grant of the rights to commercialize COVAXIN™ in Canada, Ocugen will make an upfront payment and milestone payment upon first commercial sale in Canada to Bharat Biotech, in addition to sharing the profit from sales of COVAXINTM in Canada. Similar to the US profit share arrangement, Ocugen will retain 45% of the profits from sales of COVAXINTM in Canada.

About COVAXIN™

COVAXIN™, India’s COVID-19 vaccine by Bharat Biotech, is developed in collaboration with the Indian Council of Medical Research (ICMR) – National Institute of Virology (NIV). COVAXIN™ is a highly purified and inactivated vaccine that is manufactured using a vero cell manufacturing platform. This platform has an excellent safety track record of more than 300 million doses of various vaccines supplied. Based on a traditional vaccine platform that has a long-established safety profile, COVAXIN™ continues to show strong results in all the studies conducted to date including a vaccine efficacy rate of 78% overall efficacy and 100% in severe COVID-19 disease, including hospitalizations, in second interim results of Bharat Biotech’s Phase 3 clinical trial.

In addition to generating strong immune response against multiple antigens, COVAXIN has been shown to generate memory T cell responses, for its multiple epitopes, indicating longevity and a rapid antibody response to future infections. With published data demonstrating a safety profile superior to published safety data from separate studies for several other vaccines, COVAXIN™ is packaged in multi-dose vials that can be stored at 2-8?C.

COVAXIN™ studies show potential effectiveness against three key variants of SARS-CoV-2. Scientists at the Indian Council of Medical Research (ICMR)-National Institute of Virology, using an in-vitro plaque reduction neutralization assay, have found that COVAXIN-vaccinated sera effectively neutralized the Brazil variant of SARS-CoV-2, B.1.128.2, the UK variant, B.1.1.7, as well as the Indian double mutant variant, B.1.617. These studies suggest that COVAXIN vaccination may be effective against multiple SARS-CoV-2 variants.

Based on the more than 30 million doses supplied in India and other countries, COVAXIN™ has an excellent safety record. COVAXIN™ is currently being administered under emergency use authorizations in 13 countries, and applications for emergency use authorization are pending in more than 60 additional countries.

About Ocugen, Inc.

Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. We are co-developing Bharat Biotech’s COVAXIN™ vaccine candidate for COVID-19 in the U.S. market. For more information, please visit http://ocugen.com/

About Bharat Biotech:

Bharat Biotech has established an excellent track record of innovation with more than 140 global patents, a wide product portfolio of more than 16 vaccines, 4 bio-therapeutics, registrations in more than 116 countries, and World Health Organization (WHO) Pre-qualifications. Located in Genome Valley in Hyderabad, India, a hub for the global biotech industry, Bharat Biotech has built a world-class vaccine & bio-therapeutics, research & product development, Bio-Safety Level 3 manufacturing, and vaccine supply and distribution.

Having delivered more than 6 billion doses of vaccines worldwide, Bharat Biotech continues to lead innovation and has developed vaccines for influenza H1N1, Rotavirus, Japanese Encephalitis, Rabies, Chikungunya, Zika and the world’s first tetanus-toxoid conjugated vaccine for Typhoid.

Bharat’s commitment to global social innovation programs and public private partnerships resulted in the introduction of path breaking WHO pre-qualified vaccines BIOPOLIO®, ROTAVAC® and Typbar TCV® combatting polio, rotavirus, typhoid infections, respectively. The recent acquisition of the rabies vaccine facility, Chiron Behring, from GlaxoSmithKline (GSK) has positioned Bharat Biotech as the largest rabies vaccine manufacturer in the world. To learn more about Bharat Biotech visit https://www.bharatbiotech.com/.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such forward-looking statements include information about qualitative assessments of available data, potential benefits, expectations for clinical trials, and anticipated timing of clinical trial readouts and regulatory submissions. This information involves risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preliminary and interim data (including the Phase 3 interim data referred to in this press release), including the possibility of unfavorable new clinical trial data and further analyses of existing clinical trial data; the risk that the results of in-vitro studies will not be duplicated in human clinical trials; the risk that clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when data from Bharat Biotech’s clinical trials will be published in scientific journal publications and, if so, when and with what modifications; whether the U.S. Food and Drug Administration (FDA) will be satisfied with the design of and results from preclinical and clinical studies of COVAXIN, which have been conducted by Bharat Biotech in India; whether and when any biologics license and/or emergency use authorization applications may be filed in the United States for COVAXIN and whether and when an application for authorization under interim order for emergency use will be filed in Canada; whether and when any such applications may be approved by the FDA or Health Canada; decisions by the FDA or Health Canada impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of COVAXIN in the United States or Canada, including development of products or therapies by other companies. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release.

Ocugen Contact:
Ocugen, Inc.
Sanjay Subramanian
CFO and Head of Corp. Dev.
IR@Ocugen.com


Media Contact:
LaVoieHealthScience
Lisa DeScenza
ldescenza@lavoiehealthscience.com
+1 9783955970

Release – Lineage Cell Therapeutics To Host Webinar With Therapeutic Area Experts To Discuss Retinal Tissue Restoration

Posted on by Admin


Lineage Cell Therapeutics To Host Webinar With Therapeutic Area Experts To Discuss Retinal Tissue Restoration Observed In Dry AMD Patients Treated With Opregen®

 

Webinar Scheduled for June 10, 2021 at 4pm Eastern Time / 1pm Pacific Time

CARLSBAD, Calif.–(BUSINESS WIRE)–Jun. 3, 2021– 

Lineage Cell Therapeutics, Inc.
 (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that it plans to host a webinar featuring external therapeutic area experts in age-related macular degeneration (AMD), on 
June 10, 2021 at 
4pm ET /
1pm PT. Lineage recently reported that restoration of retinal tissue has been observed in three patients enrolled in the Company’s Phase 1/2a study of its lead product candidate, OpRegen, an allogeneic retinal pigment epithelium (RPE) cell transplant therapy in development for the treatment of AMD with geographic atrophy (GA), or dry (atrophic) AMD. These new findings occurred in three of the four better baseline vision (Cohort 4) patients for whom surgeons successfully covered the majority of the area of atrophy with a suspension of OpRegen RPE cells. Outer retinal layer restoration, which was observed using high-resolution Optical Coherence Tomography (OCT), was evidenced by the presence of new areas of RPE monolayer with overlying ellipsoid zone, external limiting membrane, and outer nuclear layer, which were not present at the time of baseline assessment. These findings suggest integration of the new RPE cells with functional photoreceptors in areas that previously showed no presence of any of these cells. These effects were most prominent in the transitional areas around the primary area of GA. The webinar will feature therapeutic area experts who will discuss these findings in detail, including a review of anatomical improvements, functional activity, and additional results of treatment with OpRegen. Interested parties can access the webinar on the Events and Presentations section of Lineage’s website.

Therapeutic Area Experts, External Reviewers & Contributors

Eyal Banin, M.D., Ph.D., Director, Center for Retinal and Macular Degenerations (CRMD), Department of Ophthalmology, Hadassah-Hebrew University Medical Center.

Dr. Banin is a graduate of the 
Hebrew University-Hadassah School of Medicine, holds a Ph.D. in Neurobiology from the 
Hebrew University, and completed his ophthalmology residency at 
Hadassah Medical Center. Following a post-doctoral and medical retina fellowship at the University of Pennsylvania’s 
Scheie Eye Institute in 
Philadelphia, he was appointed head of the Medical Retina Service and the CRMD at Hadassah. His main clinical and research focus is in the field of retinal and macular degenerations, including the development and application of novel cell- and gene-based therapies for these diseases. The recipient of many research grants from Israeli and foreign institutions,  Dr. Banin has authored and published over 150 peer-reviewed articles in leading medical and scientific journals.

Jordi Monés, M.D., Ph.D., Director, Institut de la Màcula, Director and Principal Investigator, Barcelona Macula Foundation: Research for Vision.

Dr. Monés is an ophthalmologist, macula and vitreoretinal specialist, and macular and retinal degeneration researcher. Dr. Monés earned his medical degree at the 
University of Barcelona and subsequently specialized in ophthalmology at Barraquer Ophthalmology Centre. He completed his retinal specialist training at the 
Massachusetts Eye and Ear Infirmary at 
Harvard University, and at Hospital San José, 
Monterrey Institute of Technology and Higher Education. He earned his PhD degree in Medicine and Surgery at the 
University of Barcelona. Dr Monés is dedicated to fighting blindness by supporting and conducting research in retinal disease. For the last 15 years he has been one of the foremost researchers involved in clinical trials for the treatment of age-related macular degeneration. He is currently conducting Phase I, II and III clinical trials. His work has been widely published in scientific journals and he has given more than 200 presentations at international congresses. He is a member of 12 scientific societies.

Brandon Lujan, M.D., Associate Professor of Ophthalmology, School of Medicine, OHSU Casey Eye Institute.

Dr. Lujan is a medical retina specialist, scientist, and Director of the Casey Reading Center. Dr. Lujan’s area of expertise is Optical Coherence Tomography (OCT) retinal imaging, and he is the first-named inventor and co-developer of Directional OCT, a technique and device capable of creating optical contrast in photoreceptors.  Dr. Lujan has published and spoken internationally on diagnosis and management of macular diseases and has brought that expertise to bear on clinical trials. He is the creator of OCTMD, an educational resource focused on the present and future of OCT.  Dr. Lujan is a member of the 
Macula Society, 
Retina Society, the 
Association for Research and Vision in Ophthalmology, and the 
American Society of Retina Specialists.

Christopher D. Riemann, M.D., Vitreoretinal Surgeon and Fellowship Director, Cincinnati Eye Institute (CEI) and University of Cincinnati School of Medicine.

In collaboration with the other retinal surgeons at CEI,  Dr. Riemann is a principal investigator or co-investigator for many Phase II and Phase III clinical trials. He specializes in medical and surgical vitreoretinal diseases including diabetic retinopathy, macular degeneration, retinal detachment, retinopathy of prematurity, vascular diseases of the retina, uveitis, histoplasmosis, complications of anterior segment surgery, endoscopic posterior segment surgery, and ocular trauma.  Dr. Riemann is a member of the 
American Society of Retina Specialists, 
American Academy of Ophthalmology, 
Ohio State Medical Association, 
Cincinnati Academy of Medicine, 
Cincinnati Ophthalmology Society, and the 
Association for Research in Vision and Ophthalmology. His original research in the fields of Ophthalmology, Cardiology, and Endocrinology has been published in international peer reviewed scientific journals and has been presented at national scientific meetings.  Dr. Riemann has several patents for innovative surgical technologies and enjoys sharing his passion for the blend of engineering and medicine.

Michael S. Ip, M.D., Professor, Department of Ophthalmology at the David Geffen School of Medicine at the University of California – Los Angeles.

Dr. Ip is a member of the 
Doheny Eye Institute and currently serves as the Medical Director of the Doheny Image Reading Center. His research focuses on the design and conduct of clinical trials investigating treatments for diabetic retinopathy, AMD, and retinal venous occlusive disease and other retinal diseases.  Dr. Ip has assisted with the collection, analysis, and dissemination of important primary and secondary outcomes in ophthalmic clinical trials. In 2003,  Dr. Ip was selected to serve as the national protocol chair for the clinical trial conducted by the Diabetic Retinopathy Clinical Research Network (DRCR.net) comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema (protocol B). This was a landmark study and changed practice patterns in the field of ophthalmology. In 2003, his independent and investigator-initiated research group received a U-10 cooperative agreement award from the 
National Eye Institute, 
National Institutes of Health to conduct the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study. This was a multicenter, randomized, 
NIH-defined phase 3 trial which led to over 15 publications in the peer-reviewed literature and provided much needed Level 1 evidence to guide our management of retinal venous occlusive disease. In 2013, this group received funding from the NEI to conduct the SCORE2 Study. The SCORE2 Study is an 
NIH-defined phase 3 clinical trial designed to evaluate the comparative efficacy and safety of bevacizumab versus aflibercept for the treatment of macular edema secondary to central retinal vein occlusion. It has been designed to answer several questions of significant public health importance. Currently, this study group has extended the SCORE2 follow up phase to evaluate long-term safety and efficacy outcomes in central retinal vein occlusion.

Allen C. Ho, M.D. FACS, Wills Eye Hospital Attending Surgeon and Director of Retina Research, Professor of Ophthalmology, Thomas Jefferson University.

Dr. Ho maintains special interests in macular diseases, diabetic retinopathy, surgical retinal diseases and clinical trials investigating new treatments for vitreoretinal diseases including gene and cell therapies and new surgical drug delivery devices and techniques. His experience includes collaborative translational and clinical trial clinical research with expertise in study design, methodological testing, data analyses, surgical instrumentation and procedure development, execution and communication of these studies and their study results. He is the current President of The 
Retina Society and serves on its Executive Committee.  Dr. Ho has been Study Chair, Steering Committee Member or Principal Investigator of over 50 clinical trials.  Dr. Ho has served on the 
US FDA Ophthalmic Device Panel, 
American Academy of Ophthalmology (AAO) Ophthalmic Retina Technology Assessment Committee, 
AAO Retina Measures Group, AAO IRIS Registry Committee and is past Chair of the AAO Retina Subspecialty Days and Vail Vitrectomy meetings. Through the Wills Eye Hospital Retina Fellowship he has mentored over 60 retina fellows and international research trainees.  Dr. Ho has authored over 200 peer reviewed publications and several textbooks and is Editor-in-Chief of Current Opinion in Ophthalmology and Chief Medical Editor of Retina Today.

About OpRegen

OpRegen is currently being evaluated in a Phase 1/2a open-label, dose escalation safety and efficacy study of a single injection of human retinal pigment epithelium cells derived from an established pluripotent cell line and transplanted subretinally in patients with advanced dry AMD with GA. The study enrolled 24 patients into 4 cohorts. The first 3 cohorts enrolled only legally blind patients with Best Corrected Visual Acuity (BCVA) of 20/200 or worse. The fourth cohort enrolled 12 better vision patients (BCVA from 20/65 to 20/250 with smaller mean areas of GA). Cohort 4 also included patients treated with a new “thaw-and-inject” formulation of OpRegen, which can be shipped directly to sites and used immediately upon thawing, removing the complications and logistics of having to use a dose preparation facility. The primary objective of the study is to evaluate the safety and tolerability of OpRegen as assessed by the incidence and frequency of treatment emergent adverse events. Secondary objectives are to evaluate the preliminary efficacy of OpRegen treatment by assessing the changes in ophthalmological parameters measured by various methods of primary clinical relevance. OpRegen is a registered trademark of 
Cell Cure Neurosciences Ltd., a majority-owned subsidiary of 
Lineage Cell Therapeutics, Inc.

About Age-Related Macular Degeneration

Age-related macular degeneration (AMD) is an eye disease that can blur the sharp, central vision in patients and is the leading cause of vision loss in people over the age of 60. There are two forms of AMD: dry (atrophic) AMD and wet (neovascular) AMD. Dry (atrophic) AMD is the more common of the two forms, accounting for approximately 85-90% of all cases. In atrophic AMD, parts of the macula get thinner with age and accumulations of extracellular material between Bruch’s membrane and the RPE, known as drusen, increase in number and volume, leading to a progressive loss of central vision, typically in both eyes. Global sales of the two leading wet AMD therapies were in excess of 
$10 billion in 2019. Nearly all cases of wet AMD eventually will develop the underlying atrophic AMD if the newly formed blood vessels are treated correctly. There are currently no 
U.S. Food and Drug Administration, or 
European Medicines Agency, approved treatment options available for patients with atrophic AMD.

About Lineage Cell Therapeutics, Inc. 

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include three allogeneic (“off-the-shelf”) product candidates: (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; and (iii) VAC2, an allogeneic dendritic cell therapy produced from Lineage’s VAC technology platform for immuno-oncology and infectious disease, currently in Phase 1 clinical development for the treatment of non-small cell lung cancer. For more information, please visit www.lineagecell.com or follow the Company on Twitter @LineageCell.

Lineage Cell Therapeutics, Inc. IR
Ioana C. Hone
(ir@lineagecell.com)
(442) 287-8963

Solebury Trout IR
Gitanjali Jain Ogawa
(Gogawa@soleburytrout.com)
(646) 378-2949

Russo Partners – Media Relations
Nic Johnson or  David Schull
Nic.johnson@russopartnersllc.com
David.schull@russopartnersllc.com
(212) 845-4242

Source: 
Lineage Cell Therapeutics, Inc.

Throwback Thursday – Most Read in May 2021

Posted on by Admin


THROWBACK THURSDAY

Here is What You (our audience) Read the Most During May 2021

 

Visitors to Channelchek pushed two cannabis articles into the #1 and #2 most popular positions last month. The articles address two completely different areas of interest in the marijuana industry.

The first is an interesting read on how cannabis growers have adopted high-tech, even artificial intelligence, in their farming. Cannabis, like many other crops, is more marketable if grown to exacting uniformity.  AI farming helps with this goal.

 

Robotics
and AI are Being Tapped by Cannabis Growers

 

The second most popular in May concerns the federal laws surrounding cannabis production and usage. The glaring difference between laws of states that accept and welcome the industry and the federal laws that literally make the companies and the medical and recreational users all federal criminals creates a strange set of circumstances. The absence of the banking system being able to support this budding industry is also an issue that could dramatically allow it to quickly become more prosperous if changed.

 

Federal
Law Questions Still Loom for the Cannabis Industry

 

Noble Capital Markets is a Platinum sponsor of the 16th annual World
Stem Cell Summit being held virtually June 14-18th. This field of study has such potential as new uses and breakthroughs in every area of health, from aging to organ replacement, are being explored every day.  Channelchek is preparing our registered users with insight and information to get more from this event.

What
Cells Can Be Made from Stem Cells?

 

Each year the Russell reconstitution makes waves among market participants as demand for some company’s shares dramatically increase as they are added to an index that portfolio managers mimic and others are removed or qualify for a different index within the Russell family. This May through June reconstitution moves prices, so market participants need to understand what is going on.

The
Annual Russell Index Revision and Dates to Watch

Ford Motor Company announced its aggressive plans for an electric fleet of cars and trucks. This announcement is a reminder of the demand that is going to be placed on the materials needed to meet the goals of the future generation of vehicles. This article spells out the amount of additional copper needed for each vehicle and suggests mining companies for equity investors to gain exposure to this semi-precious metal.

Copper
Facing an Onslaught of Demand

 

Channelchek will continue to provide investors in the small and microcap space information and insight as to where they may look for ideas. The top-tier research provided by leading equity analysts is used by institutional portfolio managers throughout the world. Access is free to registered users.

 

 

 

Stay up to date. Follow us:

           


Stay up to date. Follow us:

Release – Esports Entertainment Group Completes Acquisition of Helix eSports and ggCircuit

Posted on by Admin

 


Esports Entertainment Group Completes Acquisition of Helix eSports and ggCircuit

 

Acquisitions significantly strengthen Company’s Play, Watch, Bet Strategy. Adds state-of-the-art esports entertainment centers, esports-focused vertical enterprise software business, best-in-class esports analytics platform, and P2P skill-based wagering platform

Newark, New Jersey–(Newsfile Corp. – June 3, 2021) – Esports Entertainment Group, Inc. (NASDAQ: GMBL) (NASDAQ: GMBLW) (or the “Company”), an esports entertainment and online gambling company, today announced the closing of its acquisition of Helix eSports LLC (“Helix eSports”) and ggCircuit LLC (“ggCircuit”).

“With the completed acquisition of Helix and ggCircuit, we have created the most diversified, US-listed esports entertainment asset in the entire ecosystem,” stated Grant Johnson, CEO of Esports Entertainment Group. “These acquisitions significantly strengthen our Play, Watch, Bet Strategy, adding state-of-the-art esports entertainment centers, an esports-focused vertical enterprise software business, a best-in-class esports analytics platform, and a player-vs-player skill-based wagering platform to our diversified asset base. Together with what we have already built, Esports Entertainment Group has unparalleled scale, and we are on our way to becoming a global industry leader.”

ggCircuit is a B2B software company that provides cloud-based management for LAN centers, a tournament platform, and integrated wallet/point-of-sale solutions for enterprise customers. ggCircuit has over 1,000 connected locations and has worked with enterprises such as GameStop, Dell, Best Buy and Lenovo as well as universities such as Ohio State, Syracuse and North Carolina. Their ggLeap product has over 60 million hours of usage by over two million unique gamers on tens of thousands of public gaming screens inside centers worldwide.

Helix eSports owns five esports centers, including two of the five largest centers in the US, where they deliver world-class customer service, esports programming and gaming infrastructure. Helix offers a variety of experiences including casual play, competitive tournaments, STEM programming, high school leagues, large groups and esports bootcamps all with the goal of leveling the playing field in esports and providing equitable access to technology. Their centers have become the destination for social and competitive gamers alike with monthly tournaments and unique experiences.

Helix also owns Genji Analytics (“Genji”), an esports-proven, publisher-trusted analytics provider. Using sophisticated computer vision, natural language processing, and machine learning tools, Genji delivers cutting-edge broadcast optimization and talent scouting analytics. Genji works with leading esports publishers and sports leagues, such as FIFA and the NBA 2K League, to power activities like combines, drafts and data-driven business decisions. Genji has also launched products into Helix eSports Centers that create customized tournament experiences, leveraging both idle computing capacity and unique proprietary data sources. Revenue streams include platform sales to publishers and leagues with plans to expand to all competitive players looking to enhance their gameplay through analysis, fair competition, and roster optimization.

The acquisition also includes LANduel, Helix’s proprietary player-vs-player wagering platform, built in Unity, that allows for skill-based wagering on third-party video games. LANduel’s consumer facing application enforces strict four-factor authentication to ensure fair play and ID verification. LANduel also holds close relationships with several major game publishers to ensure events and wagering follow community guidelines. LANduel is currently working alongside the New Jersey Department of Gaming Enforcement on a pilot program. Once the model is proven at the Helix eSports locations, LANduel can easily be scaled to other centers throughout the US across the ggCircuit network, and eventually into the homes of gamers through ggCircuit’s proprietary at home product suite.

About Esports Entertainment Group

Esports Entertainment Group is a full stack esports and online gambling company fueled by the growth of video-gaming and the ascendance of esports with new generations. Our mission is to help connect the world at large with the future of sports entertainment in unique and enriching ways that bring fans and gamers together. Esports Entertainment Group and its affiliates are well-poised to help fans and players to stay connected and involved with their favorite esports. From traditional sports partnerships with professional NFL/NHL/NBA/FIFA teams, community-focused tournaments in a wide range of esports, and boots-on-the-ground LAN cafes, EEG has influence over the full-spectrum of esports and gaming at all levels. The Company maintains offices in New Jersey, the UK and Malta. For more information visit 
www.esportsentertainmentgroup.com.

FORWARD-LOOKING STATEMENTS

The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The safe harbor for forward-looking statements contained in the Securities Litigation Reform Act of 1995 protects companies from liability for their forward-looking statements if they comply with the requirements of the Act.

Contact:

U.S. Investor Relations
RedChip Companies, Inc.
Dave Gentry
407-491-4498

dave@redchip.com

Media & Investor Relations Inquiries
Jeff@esportsentertainmentgroup.com